The São Paulo-based Butantan Institute – which is running final-stage clinical trials for CoronaVac, manufactured by Beijing-based Sinovac – submitted new data to Brazil’s health regulator on Tuesday, listing an efficacy rate of 50.4 per cent. The numbers were confirmed at a press conference by officials from the research institute, which is funded by the São Paulo state government.
